Video: CRESTOR(R) Reduced Risk of Blood Clots in the Veins
Posted on: Sunday, 29 March 2009, 11:50 CDT
Venous thromboembolism, a serious and sometimes fatal condition, occurs when a blood clot forms in a vein. The most common form of VTE is deep vein thrombosis (DVT), which occurs in the 'deep veins' usually in the legs or pelvis. An embolism is created if the clot travels through the venous system. Blood clots lodging in the lungs are known as a pulmonary embolism (PE). Estimates suggest that at least 350,000 and as many as 600,000 Americans annually develop DVT/PE, and at least 100,000 deaths are thought to be related to these diseases each year.
Additional results of this secondary endpoint analysis of
"This is the first time a statin has been shown to reduce the risk of VTE
in a randomized, prospective study," said
Rosuvastatin 20mg was well tolerated in nearly 9,000 patients during the
course of the
ABOUT
AstraZeneca has previously announced that it expects to file a regulatory
submission including the
ABOUT CRESTOR (ROSUVASTATIN CALCIUM):
Studies have previously shown that CRESTOR significantly lowered LDL-C, had a significant effect on raising HDL-C and slowed the progression of atherosclerosis, the build-up of plaque in the arteries.
CRESTOR has now received regulatory approval in over 90 countries. More than 13 million patients have been prescribed CRESTOR worldwide. Data from clinical trials and real world use shows that the safety profile for CRESTOR is in line with other marketed statins.
IMPORTANT SAFETY INFORMATION:
CRESTOR is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and TG levels and to increase HDL-C in adult patients with primary hyperlipidemia and mixed dyslipidemia. CRESTOR is also indicated as an adjunct to diet to slow the progression of atherosclerosis as part of a treatment strategy to lower Total-C and LDL-C to target levels. CRESTOR is not approved to prevent cardiovascular morbidity and mortality.
CRESTOR is contraindicated in patients with a known hypersensitivity to any component of this product, in patients with active liver disease, which may include unexplained persistent elevations of hepatic transaminase levels, in women who are pregnant or may become pregnant, and in nursing mothers.
Cases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported with HMG-CoA reductase inhibitors, including CRESTOR. These risks can occur at any dose level, but are increased at the highest dose (40 mg).
CRESTOR should be prescribed with caution in patients with predisposing factors for myopathy (eg, age Greater Than or Equal To 65 years, inadequately treated hypothyroidism, renal impairment). The risk of myopathy during treatment with CRESTOR may be increased with concurrent administration of some other lipid-lowering therapies (fibrates or niacin), gemfibrozil, cyclosporine, or lopinavir/ritonavir.
Therapy with CRESTOR should be discontinued if markedly elevated CK levels occur or myopathy is diagnosed or suspected. All patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. It is recommended that liver enzyme tests be performed before and at 12 weeks following both the initiation of therapy and any elevation of dose, and periodically (e.g., semiannually) thereafter. Should an increase in ALT or AST of Greater Than 3 times ULN persist, reduction of dose or withdrawal of CRESTOR is recommended. CRESTOR should be used with caution in patients who consume substantial quantities of alcohol.
CRESTOR 40 mg should be used only for those patients not achieving their LDL-C goal with 20 mg. Patients initiating CRESTOR therapy or switching from another statin should begin treatment with CRESTOR at the appropriate starting dose.
In the controlled clinical trials database, the most common adverse reactions were headache (3.7%), myalgia (3.1%), abdominal pain (2.6%), asthenia (2.5%), and nausea (2.2%).
Please see accompanying full Prescribing Information. If you have any questions concerning CRESTOR, please contact AstraZeneca at 1-800-237-8898. CRESTOR is a registered trademark of the AstraZeneca group of companies.
ABOUT ASTRAZENECA:
AstraZeneca (NYSE: AZN) is engaged in the research, development,
manufacturing and marketing of meaningful prescription medicines and in the
supply of healthcare services. AstraZeneca is one of the world's leading
pharmaceutical companies with global healthcare sales of
For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com.
SOURCE AstraZeneca
Source: PR Newswire
Related Articles
- New Analysis Suggests That Improvements in Kidney Function in Patients Treated With Lipitor Strongly Correlate With a Reduced Risk of Major Cardiovascular Events
- Brigham and Women's Hospital and Celera Publish Results Demonstrating That Carriers of a Variant of the LPA Gene Have More Than Two-Fold Higher Risk of Major Cardiovascular Events and That This Risk is Eliminated By Aspirin Therapy
- Ichor Melanoma Vaccine Clinical Trial Moves to Highest Dose Level
- Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients With Higher-Risk Myelodysplastic Syndromes (MDS)
- ACTOS(R) (Pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients With Type 2 Diabetes
- Sepsis Drug Fails to Help Patients at Low Risk of Death
- ICU Patients at Significant Risk for Adverse Events and Serious Errors
- Cost-Effectiveness in Italy of Preventive Treatment With Ramipril in Patients at High Risk of Cardiovascular Events
- European Working Time Directive May Put Doctors' and Patients' Lives at Risk
- Recall Rattles Patients ; Vioxx Heart Risk Should Vanish By Discontinuing Use of Drug, Local Physician Says.
 |
 |
User Comments (0)
RSS Feeds